Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07792317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation

Study acronym: NEWHOPE
StatusRecruiting
PhaseNot applicable
Started2025-11-17
View on ClinicalTrials.gov ↗
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function. Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.
Trial Details
NCT Number NCT07792317
Lead Sponsor Vivalyx GmbH
Conditions Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures, End Stage Renal Disease (ESRD)
Enrollment 15 participants
Start Date 2025-11-17
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-28